FY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by Analyst

Axovant Sciences Ltd (NASDAQ:AXON) – Stock analysts at Oppenheimer raised their FY2018 earnings estimates for shares of Axovant Sciences in a report issued on Tuesday. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will post earnings of ($2.30) per share for the year, up from their previous forecast of ($2.34). Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Axovant Sciences’ Q4 2018 earnings at ($0.47) EPS, FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.28) EPS, FY2021 earnings at ($1.04) EPS and FY2022 earnings at ($0.57) EPS.

A number of other research firms also recently commented on AXON. HC Wainwright restated a “buy” rating on shares of Axovant Sciences in a report on Thursday, October 19th. Jefferies Group downgraded Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target for the company. in a report on Thursday, December 21st. Cowen downgraded Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Friday, January 12th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Wednesday, January 31st. Finally, ValuEngine downgraded Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.61.

Axovant Sciences (AXON) traded down $0.18 during mid-day trading on Thursday, hitting $1.63. The stock had a trading volume of 1,419,900 shares, compared to its average volume of 2,165,688. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.58 and a quick ratio of 5.94. Axovant Sciences has a 1-year low of $1.47 and a 1-year high of $27.98.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Axovant Sciences by 99.8% during the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after purchasing an additional 1,454,454 shares during the last quarter. OxFORD Asset Management LLP lifted its position in shares of Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Eagle Asset Management Inc. bought a new position in shares of Axovant Sciences during the third quarter worth about $4,471,000. Deutsche Bank AG lifted its position in shares of Axovant Sciences by 7.0% during the fourth quarter. Deutsche Bank AG now owns 548,728 shares of the biotechnology company’s stock worth $2,891,000 after purchasing an additional 35,878 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Axovant Sciences by 52.8% during the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock worth $12,682,000 after purchasing an additional 188,945 shares during the last quarter. 96.82% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/15/fy2018-eps-estimates-for-axovant-sciences-ltd-axon-lifted-by-analyst.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply